Analysis: Lincoln Pharmaceuticals Limited

Growth thesis

Lincoln Pharmaceuticals Ltd is a debt-free Indian pharma formulator scaling through domestic branded generics, Cephalosporin injectables (targeting INR90-100 crores revenue in FY27 from INR45 crores currently), and regulated market CDMO/CMO projects (24-25 commercialized projects). Growth hinges on Cepha block expansion, Canada/regulated markets growing to $10-15 million annually by FY27, and EU reinspection (May-June 2026) unlocking EU market access. Revenue will reach INR1,000 crores by FY28 via existing plant optimization (INR750-800 crores capacity) and inorganic opportunities. EBITDA margins of 15-18% depend on forex stability and product mix. Key execution risk is EU reinspection delays or currency volatility in African markets.

Why is Lincoln Pharmaceuticals Limited stock rising?

• Target revenue of INR1,000 crores, aiming to achieve within next 2-3 years with possible 6-month delay
• Targeting annual growth of 12% to 18%
• Cepha block expected to reach INR90-100 crores revenue next year from current INR45 crores
• Domestic business expected to grow 10-15% next year from existing facility with new dossiers
• New dedicated R&D center to be operational within 2-2.5 months

Research report

companyname: Lincoln Pharmaceuticals Limited ticker: LINCOLN sector: Pharmaceuticals Lincoln Pharmaceuticals Limited is an Indian branded generic pharmaceutical company founded in 1979. It manufactures and markets its own formulations across over 60 countries, operating from two manufacturing facilities in Gujarat—Khatraj (Ahmedabad) and Mehsana. The company employs over 1,700 people as of FY25. Lincoln does not engage in third-party manufacturing for domestic customers. As the management stat...

Catalysts

capex, margin expansion, regulatory approval, debt reduction